세계의 골다공증 치료제 시장 보고서(2025년)

Osteoporosis Drugs Global Market Report 2025

US $ 4,490 ￦ 6,265,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,056,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,846,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

골다공증 치료제 시장 규모는 향후 수년간 안정적인 성장을 보일 것으로 예상되며, 2029년에는 연평균 3.1%의 연평균 복합 성장률(CAGR)로 144억 8,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 지속적인 고령화 추세, 치료 옵션의 발전, 남성의 뼈 건강에 대한 관심 증가, 환자 교육 및 권한 부여, 세계 의료 정책 및 보험 적용에 기인하는 것으로 추정됩니다. 예측 기간의 주요 동향으로는 맞춤형 의료에 대한 접근, 병용요법 모색, 골절 예방 전략의 중요성, 신규 신약 타깃에 대한 R&D 투자, 의약품 개발을 위한 공동 연구 등을 꼽을 수 있습니다.

골다공증 유병률 증가는 골다공증 치료제 시장의 성장을 가속할 것으로 예상됩니다. 골다공증은 골밀도와 골량의 감소, 골질 및 골구조의 변화를 특징으로 하는 골질환입니다. 칼슘 섭취가 적은 사람은 골다공증 발병 위험이 높습니다. 이러한 골다공증 치료제는 골밀도를 높이고 골절 가능성을 낮추는 역할을 합니다. 예를 들어 2024년 6월 호주 정부 기관인 호주 보건 복지 연구소는 골다공증이 2022년 2,659명, 인구 10만 명당 10.2명의 사망 원인으로 전체 사망의 1.4%를 차지한다고 보고했습니다. 이처럼 골다공증 유병률 증가가 골다공증 치료제 시장의 성장을 가속하고 있습니다.

고령화의 진전은 당분간 골다공증 치료제 시장 성장의 중요한 촉진요인이 될 것으로 예상됩니다. 고령화는 주로 출산율 감소와 평균수명 연장의 영향을 받아 인구의 평균 연령이 상승하는 것을 의미합니다. 골다공증의 위험은 골밀도의 자연적 감소로 인해 노화와 함께 증가하는 것으로 알려져 있습니다. 노인 인구 증가는 골다공증 치료제에 대한 수요 증가에 기여하고 있습니다. 예를 들어 스위스에 본부를 둔 정부 간 기구인 세계보건기구(WHO)의 2022년 자료에 따르면 60세 이상 세계 인구는 10억 명에서 14억 명으로 증가했으며, 2050년 예측에 따르면 세계 60세 이상 인구는 두 배로 증가하여 21억 명에 달할 것으로 예상됩니다. 따라서 고령화 인구 증가는 골다공증 치료제 시장의 성장을 가속하는 중요한 요인으로 부상하고 있습니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, Covid, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 골다공증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
• 최종 용도 산업의 분석
• 세계의 골다공증 치료제 시장 : 성장률 분석
• 세계의 골다공증 치료제 시장 실적 : 규모와 성장, 2019-2024
• 세계의 골다공증 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 골다공증 치료제 TAM(Total Addressable Market)

제6장 시장 세분화

• 세계의 골다공증 치료제 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 비스포스포네이트
• 선택적 에스트로겐 수용체 모듈레이터(SERM)
• RANK 리간드 저해제
• 세계의 골다공증 치료제 시장 관리별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 경구
• 주사 가능
• 세계의 골다공증 치료제 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 소매 약국
• 병원 약국
• 온라인 판매
• 세계의 골다공증 치료제 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 원발성 골다공증
• 연발성 골다공증
• 세계의 골다공증 치료제 시장 비스포스포네이트의 유형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Alendronate
• Risedronate
• Ibandronate
• 졸레드론산
• 세계의 골다공증 치료제 시장 선택적 에스트로겐 수용체 모듈레이터(SERM)의 유형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Raloxifene
• Bazedoxifene
• 세계의 골다공증 치료제 시장 RANK 리간드 저해제의 유형별 서브 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• Denosumab

제7장 지역별·국가별 분석

• 세계의 골다공증 치료제 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 골다공증 치료제 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 골다공증 치료제 시장 : 경쟁 구도
• 골다공증 치료제 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 대기업과 혁신적 기업

• GlaxoSmithKline PLC
• Eli Lilly and Company
• Amgen Inc.
• Novo Nordisk A/S
• Asahi Kasei Pharma Corporation
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd
• Mylan N.V.
• Daiichi Sankyo Company Limited
• Sun Pharmaceutical Industries Ltd.
• Ipsen
• Kyowa Kirin Co Ltd.
• Dr. Reddy's Laboratories Ltd.
• Cipla Limited
• Recordati S.p.A.

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 골다공증 치료제 시장 2029 : 새로운 기회를 제공하는 국가
• 골다공증 치료제 시장 2029 : 새로운 기회를 제공하는 부문
• 골다공증 치료제 시장 2029 : 성장 전략
  • 시장 동향에 기반한 전략
  • 경쟁사 전략

제36장 부록

KSA

영문 목차

영문목차

Osteoporosis drugs are medications designed to increase bone mineral density, reducing the risk of fractures. They are used both in the treatment and prevention of fractures, aiming to strengthen bones and prevent bone loss associated with osteoporosis.

The primary categories of osteoporosis drugs comprise bisphosphonates, selective estrogen receptor modulators (SERMS), and rank ligand inhibitors. Bisphosphonates are a class of medications aimed at addressing bone conditions such as osteopenia or osteoporosis, both characterized by fragile or thin bones susceptible to fractures. These drugs are available in oral and intravenous forms, distributed through diverse channels such as retail pharmacies, hospital dispensaries, and online sales platforms. They find application in treating both primary and secondary osteoporosis.

The osteoporosis drugs market research report is one of a series of new reports from The Business Research Company that provides osteoporosis drugs market statistics, including osteoporosis drugs industry global market size, regional shares, competitors with a osteoporosis drugs market share, detailed osteoporosis drugs market segments, market trends and opportunities, and any further data you may need to thrive in the osteoporosis drugs industry. This osteoporosis drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The osteoporosis drugs market size has grown steadily in recent years. It will grow from $12.33 billion in 2024 to $12.8 billion in 2025 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to aging population, increased awareness and diagnosis, lifestyle factors, government initiatives and healthcare policies.

The osteoporosis drugs market size is expected to see steady growth in the next few years. It will grow to $14.48 billion in 2029 at a compound annual growth rate (CAGR) of 3.1%. The growth in the forecast period can be attributed to continued aging population trends, advancements in treatment options, increased focus on men's bone health, patient education and empowerment, global health policies and insurance coverage. Major trends in the forecast period include personalized medicine approaches, exploration of combination therapies, focus on fracture prevention strategies, R&D investment in novel drug targets, collaborations for drug development.

An increase in the prevalence of osteoporosis is anticipated to drive the growth of the osteoporosis drug market. Osteoporosis is a bone condition characterized by a decrease in bone mineral density and mass or changes in bone quality and structure. Individuals with low calcium intake are at a higher risk of developing osteoporosis. These osteoporosis medications work to enhance bone mineral density and reduce the likelihood of fractures. For example, in June 2024, the Australian Institute of Health and Welfare, an Australian government agency, reported that osteoporosis was responsible for 2,659 deaths in 2022, which equates to 10.2 deaths per 100,000 people, accounting for 1.4% of all deaths. Thus, the rising prevalence of osteoporosis is propelling the growth of the osteoporosis drug market.

The rising aging population is anticipated to be a significant driver for the growth of the osteoporosis drug market in the foreseeable future. The aging population refers to an increase in the median age of a population, primarily influenced by declining fertility rates and prolonged life expectancy. Osteoporosis risk is known to escalate with age due to the natural decline in bone density. The expanding demographic of elderly individuals contributes to a growing demand for osteoporosis medications. For example, in 2022, data from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that the global population aged 60 years and over increased from 1 billion to 1.4 billion. Projections for 2050 anticipate a doubling of the world's population of individuals aged 60 years and older to reach 2.1 billion. Hence, the increasing aging population emerges as a key factor driving the growth of the osteoporosis drug market.

Key players in the osteoporosis drugs industry are driving forward with innovative approaches to address this market. An example of this progress is seen in Apotex Inc., a Canadian pharmaceutical giant, which introduced the Teriparatide Injectable for Osteoporosis Treatment in November 2023. This pre-filled pen, containing 250 mcg/mL, facilitates 28 daily doses of 20 mcg each, specifically designed for single-patient usage. This offering aims to provide affordable access to much-needed treatment for patients dealing with osteoporosis.

Major players in the osteoporosis drug market are strategically leveraging partnerships to ensure dependable services for their clientele. A case in point is the December 2022 collaboration between Chugai Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, and Towa Pharmaceutical Co. Ltd., a Japan-based manufacturer specializing in generic drug development. This alliance facilitated the introduction of Edirol Tablet for osteoporosis treatment. Chugai's production of Edirol tablets, supplied to Towa, showcases this active vitamin D3 derivative's efficacy in enhancing calcium and bone metabolism. This joint effort significantly contributes to diversifying treatment options available in the osteoporosis drug market, addressing the needs of individuals dealing with this condition.

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company that offers various pharmaceutical products, acquired EffRx Pharmaceuticals for an undisclosed amount. With this acquisition, Abiogen Pharma intends to bolster its international presence, enhance its product offerings in bone health, leverage synergies for more effective drug development, and concentrate on rare diseases. EffRx Pharmaceuticals, a Switzerland-based company, specializes in creating innovative treatments for osteoporosis, aiming to improve bone density and minimize fracture risk. Their therapies focus on specific biological pathways to promote bone health in patients suffering from this condition.

Major companies operating in the osteoporosis drugs market include Pfizer Inc., F. Hoffmann La Roche Ltd., Merck & Co Inc., Novartis AG, Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Asahi Kasei Pharma Corporation, Viatris Inc., Teva Pharmaceutical Industries Ltd, Mylan N.V., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Ipsen, Kyowa Kirin Co Ltd., Dr. Reddy's Laboratories Ltd., Cipla Limited, Recordati S.p.A., Cadila Healthcare Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Sunovion Pharmaceuticals Inc., Theramex, Radius Health Inc., Strides Pharma Science Limited, Apotex Inc.

North America was the largest region in the osteoporosis market in 2024. The regions covered in the osteoporosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the osteoporosis drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The osteoporosis drugs market consists of sales of antiresorptive drugs and anabolic drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Osteoporosis Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on osteoporosis drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for osteoporosis drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The osteoporosis drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Bisphosphonates; Selective Estrogen Receptor Modulators (SERMs); RANK Ligand Inhibitors
• 2) By Administration: Oral; Injectable
• 3) By Distribution Channel: Retail Pharmacies; Hospital Pharmacies; Online Sales
• 4) By Application: Primary Osteoporosis; Secondary Osteoporosis
• Subsegments:
• 1) By Bisphosphonates: Alendronate; Risedronate; Ibandronate; Zoledronic Acid
• 2) By Selective Estrogen Receptor Modulators (SERMs): Raloxifene; Bazedoxifene
• 3) By RANK Ligand Inhibitors: Denosumab
• Companies Mentioned: Pfizer Inc.; F. Hoffmann La Roche Ltd.; Merck & Co Inc.; Novartis AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Osteoporosis Drugs Market Characteristics

3. Osteoporosis Drugs Market Trends And Strategies

4. Osteoporosis Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Osteoporosis Drugs Growth Analysis And Strategic Analysis Framework

• 5.1. Global Osteoporosis Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Osteoporosis Drugs Market Growth Rate Analysis
• 5.4. Global Osteoporosis Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Osteoporosis Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Osteoporosis Drugs Total Addressable Market (TAM)

6. Osteoporosis Drugs Market Segmentation

• 6.1. Global Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bisphosphonates
• Selective Estrogen Receptor Modulators (SERMs)
• RANK Ligand Inhibitors
• 6.2. Global Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.3. Global Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Retail Pharmacies
• Hospital Pharmacies
• Online Sales
• 6.4. Global Osteoporosis Drugs Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Osteoporosis
• Secondary Osteoporosis
• 6.5. Global Osteoporosis Drugs Market, Sub-Segmentation Of Bisphosphonates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Alendronate
• Risedronate
• Ibandronate
• Zoledronic Acid
• 6.6. Global Osteoporosis Drugs Market, Sub-Segmentation Of Selective Estrogen Receptor Modulators (SERMs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Raloxifene
• Bazedoxifene
• 6.7. Global Osteoporosis Drugs Market, Sub-Segmentation Of RANK Ligand Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Denosumab

7. Osteoporosis Drugs Market Regional And Country Analysis

• 7.1. Global Osteoporosis Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Osteoporosis Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Osteoporosis Drugs Market

• 8.1. Asia-Pacific Osteoporosis Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Osteoporosis Drugs Market

• 9.1. China Osteoporosis Drugs Market Overview
• 9.2. China Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Osteoporosis Drugs Market

• 10.1. India Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Osteoporosis Drugs Market

• 11.1. Japan Osteoporosis Drugs Market Overview
• 11.2. Japan Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Osteoporosis Drugs Market

• 12.1. Australia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Osteoporosis Drugs Market

• 13.1. Indonesia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Osteoporosis Drugs Market

• 14.1. South Korea Osteoporosis Drugs Market Overview
• 14.2. South Korea Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Osteoporosis Drugs Market

• 15.1. Western Europe Osteoporosis Drugs Market Overview
• 15.2. Western Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Osteoporosis Drugs Market

• 16.1. UK Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Osteoporosis Drugs Market

• 17.1. Germany Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Osteoporosis Drugs Market

• 18.1. France Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Osteoporosis Drugs Market

• 19.1. Italy Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Osteoporosis Drugs Market

• 20.1. Spain Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Osteoporosis Drugs Market

• 21.1. Eastern Europe Osteoporosis Drugs Market Overview
• 21.2. Eastern Europe Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Osteoporosis Drugs Market

• 22.1. Russia Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Osteoporosis Drugs Market

• 23.1. North America Osteoporosis Drugs Market Overview
• 23.2. North America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Osteoporosis Drugs Market

• 24.1. USA Osteoporosis Drugs Market Overview
• 24.2. USA Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Osteoporosis Drugs Market

• 25.1. Canada Osteoporosis Drugs Market Overview
• 25.2. Canada Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Osteoporosis Drugs Market

• 26.1. South America Osteoporosis Drugs Market Overview
• 26.2. South America Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Osteoporosis Drugs Market

• 27.1. Brazil Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Osteoporosis Drugs Market

• 28.1. Middle East Osteoporosis Drugs Market Overview
• 28.2. Middle East Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Osteoporosis Drugs Market

• 29.1. Africa Osteoporosis Drugs Market Overview
• 29.2. Africa Osteoporosis Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Osteoporosis Drugs Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Osteoporosis Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Osteoporosis Drugs Market Competitive Landscape And Company Profiles

• 30.1. Osteoporosis Drugs Market Competitive Landscape
• 30.2. Osteoporosis Drugs Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Osteoporosis Drugs Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline PLC
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. Novo Nordisk A/S
• 31.5. Asahi Kasei Pharma Corporation
• 31.6. Viatris Inc.
• 31.7. Teva Pharmaceutical Industries Ltd
• 31.8. Mylan N.V.
• 31.9. Daiichi Sankyo Company Limited
• 31.10. Sun Pharmaceutical Industries Ltd.
• 31.11. Ipsen
• 31.12. Kyowa Kirin Co Ltd.
• 31.13. Dr. Reddy's Laboratories Ltd.
• 31.14. Cipla Limited
• 31.15. Recordati S.p.A.

32. Global Osteoporosis Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Osteoporosis Drugs Market

34. Recent Developments In The Osteoporosis Drugs Market

35. Osteoporosis Drugs Market High Potential Countries, Segments and Strategies

• 35.1 Osteoporosis Drugs Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Osteoporosis Drugs Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Osteoporosis Drugs Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료